Firefly neuroscience achieves multi-fold database, ip portfolio, and commercial footprint expansion through acquisition of evoke neuroscience, inc.

Builds upon firefly's recent acceptance into the nvidia connect program marks next major step toward building a proprietary foundation model of the human brain kenmore, n.y., may 05, 2025 (globe newswire) -- firefly neuroscience, inc. (“firefly,” or the “company”) (nasdaq: aiff), an artificial intelligence (“ai”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announce its acquisition of evoke neuroscience, inc. (“evoke”), a medical device company developing and commercializing technologies to aid in the comprehensive assessment of brain health.
AIFF Ratings Summary
AIFF Quant Ranking